{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:7392"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:7392","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"The role of microvascular tumour endothelium in the recruitment of CD8+ T lymphocytes in colorectal cancer","abstract":"Tumour endothelial cells (TEC) display a distinct and angiogenic phenotype. They also permit trafficking of anti-tumour CD8+ T-lymphocytes into tumour stroma. I aimed to develop and validate an isolation technique and in vitro model of primary human colorectal TEC, characterize the TEC phenotype, and investigate intratumoural micro-environmental signals regulating CD8+ T-cell recruitment by TEC. Flow cytometry, ELISA and QPCR revealed CD31, VWF, CD105, VEGFR’s, VE-Cadherin, CD13 and tumour specific marker TEM8 expression by colorectal TEC. TEC and tumour associated fibroblast (TAFB) produced higher concentrations of IL-6 and CCL2/MCP-1. Static and flow-based assays, demonstrated increased CD8+ T-cell adhesion by TEC and adhesion was augmented after conditioning with CRC derived TAFB supernatant. IL-6 and CCL2/MCP-1 blockade supressed CD8 T-cell adhesion. Endothelin-1 (ET1) was produced by TAFB and Endothelin Receptor B (ETB) was preferentially expressed by CRC endothelium, blockade of which, resulted in significantly increased ICAM-1 expression and CD8+ T-cell adhesion to TEC. My validated in vitro TEC model confirms that CRC TEC has a unique phenotype influenced by the tumour microenvironment and that ETB inhibition may facilitate increased recruitment of CD8+ T-lymphocytes into the tumour stroma. This commands further investigation with the aim of developing an anti-cancer therapy in CRC.","abstract_html":"Tumour endothelial cells (TEC) display a distinct and angiogenic phenotype. They also permit trafficking of anti-tumour CD8+ T-lymphocytes into tumour stroma. I aimed to develop and validate an isolation technique and in vitro model of primary human colorectal TEC, characterize the TEC phenotype, and investigate intratumoural micro-environmental signals regulating CD8+ T-cell recruitment by TEC. Flow cytometry, ELISA and QPCR revealed CD31, VWF, CD105, VEGFR’s, VE-Cadherin, CD13 and tumour specific marker TEM8 expression by colorectal TEC. TEC and tumour associated fibroblast (TAFB) produced higher concentrations of IL-6 and CCL2/MCP-1. Static and flow-based assays, demonstrated increased CD8+ T-cell adhesion by TEC and adhesion was augmented after conditioning with CRC derived TAFB supernatant. IL-6 and CCL2/MCP-1 blockade supressed CD8 T-cell adhesion. Endothelin-1 (ET1) was produced by TAFB and Endothelin Receptor B (ETB) was preferentially expressed by CRC endothelium, blockade of which, resulted in significantly increased ICAM-1 expression and CD8+ T-cell adhesion to TEC. My validated in vitro TEC model confirms that CRC TEC has a unique phenotype influenced by the tumour microenvironment and that ETB inhibition may facilitate increased recruitment of CD8+ T-lymphocytes into the tumour stroma. This commands further investigation with the aim of developing an anti-cancer therapy in CRC.","abstract_has_math":false,"creators":["Hepburn, Elizabeth Amanda"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2017,"date_issued":"2017-07","date_published":"2017-07","updated_at":"2026-11-19T09:29:25Z","subjects":["QH301 Biology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/7392/5/Hepburn17PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A7392","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["cancer_research_uk"]},{"key":"dc:creator","label":"Author","values":["Hepburn, Elizabeth Amanda"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2017-07"]},{"key":"dc:date.issued","label":"Date","values":["2017-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/7392/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["QH301 Biology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/7392/5/Hepburn17PhD.pdf","http://etheses.bham.ac.uk//id/eprint/7392/1/Decl_IS_Hepburn17PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Tumour endothelial cells (TEC) display a distinct and angiogenic phenotype. They also permit trafficking of anti-tumour CD8+ T-lymphocytes into tumour stroma. I aimed to develop and validate an isolation technique and in vitro model of primary human colorectal TEC, characterize the TEC phenotype, and investigate intratumoural micro-environmental signals regulating CD8+ T-cell recruitment by TEC. Flow cytometry, ELISA and QPCR revealed CD31, VWF, CD105, VEGFR’s, VE-Cadherin, CD13 and tumour specific marker TEM8 expression by colorectal TEC. TEC and tumour associated fibroblast (TAFB) produced higher concentrations of IL-6 and CCL2/MCP-1. Static and flow-based assays, demonstrated increased CD8+ T-cell adhesion by TEC and adhesion was augmented after conditioning with CRC derived TAFB supernatant. IL-6 and CCL2/MCP-1 blockade supressed CD8 T-cell adhesion. Endothelin-1 (ET1) was produced by TAFB and Endothelin Receptor B (ETB) was preferentially expressed by CRC endothelium, blockade of which, resulted in significantly increased ICAM-1 expression and CD8+ T-cell adhesion to TEC. My validated in vitro TEC model confirms that CRC TEC has a unique phenotype influenced by the tumour microenvironment and that ETB inhibition may facilitate increased recruitment of CD8+ T-lymphocytes into the tumour stroma. This commands further investigation with the aim of developing an anti-cancer therapy in CRC."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["The role of microvascular tumour endothelium in the recruitment of CD8+ T lymphocytes in colorectal cancer"]}]}],"canonical_facts":{"dc:contributor.sponsor":["cancer_research_uk"],"dc:creator":["Hepburn, Elizabeth Amanda"],"dc:date":["2017-07"],"dc:date.issued":["2017-07"],"dc:description.abstract":["Tumour endothelial cells (TEC) display a distinct and angiogenic phenotype. They also permit trafficking of anti-tumour CD8+ T-lymphocytes into tumour stroma. I aimed to develop and validate an isolation technique and in vitro model of primary human colorectal TEC, characterize the TEC phenotype, and investigate intratumoural micro-environmental signals regulating CD8+ T-cell recruitment by TEC. Flow cytometry, ELISA and QPCR revealed CD31, VWF, CD105, VEGFR’s, VE-Cadherin, CD13 and tumour specific marker TEM8 expression by colorectal TEC. TEC and tumour associated fibroblast (TAFB) produced higher concentrations of IL-6 and CCL2/MCP-1. Static and flow-based assays, demonstrated increased CD8+ T-cell adhesion by TEC and adhesion was augmented after conditioning with CRC derived TAFB supernatant. IL-6 and CCL2/MCP-1 blockade supressed CD8 T-cell adhesion. Endothelin-1 (ET1) was produced by TAFB and Endothelin Receptor B (ETB) was preferentially expressed by CRC endothelium, blockade of which, resulted in significantly increased ICAM-1 expression and CD8+ T-cell adhesion to TEC. My validated in vitro TEC model confirms that CRC TEC has a unique phenotype influenced by the tumour microenvironment and that ETB inhibition may facilitate increased recruitment of CD8+ T-lymphocytes into the tumour stroma. This commands further investigation with the aim of developing an anti-cancer therapy in CRC."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/7392/5/Hepburn17PhD.pdf","http://etheses.bham.ac.uk//id/eprint/7392/1/Decl_IS_Hepburn17PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/7392/"],"dc:subject":["QH301 Biology","RC0254 Neoplasms. Tumors. Oncology (including Cancer)"],"dcterms:accessrights":["public","staffonly"],"dc:title":["The role of microvascular tumour endothelium in the recruitment of CD8+ T lymphocytes in colorectal cancer"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:29:25Z"}